Kobalt, a music publishing and rights management company, has raised a $60 million Series C round from Google Ventures, Michael Dell’s MSD Capital and MSDC Management. The company will use the funds to scale its technology offerings. Kobalt has previously raised $66 million. “We take great pride in the fact that Google Ventures and MSD Capital both share our vision of technology and transparency working together to create a new industry structure in today’s complex digital world,” said Willard Ahdritz, Kobalt founder and CEO. “We are relentless in our mission to increase trust between the music and technology industries in order to build a new infrastructure that benefits fans, creators, rights owners and DSPs, all together.”
Nasty Gal, an online women’s clothing store, has raised $16 million from former Apple retail boss Ron Johnson and existing investor Index Ventures among other, Re/code has reported. Nasty Gal previously raised $40 million led by Index in 2012, and experienced a difficult 2013 with slowing revenue growth and layoffs.
Skully, which has developed a motorcycle helmet fused with wearable technology, has raised $11 million in funding led by Intel Capital and Walden Riverwood Ventures. Eastlink Capital, Western Technology Investments, Techstars and Formation 8 also participated in the round of investment. The helmet features a display floating in front of the rider’s eyes, and shows a rear view live stream and a GPS, among other features.
Chiasma, a biopharma company, has closed a $70 million Series E financing round. Rock Springs Capital and Sofinnova Ventures were joined by existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners in the round. The company’s main product is octreotide capsules for people suffering from acromegaly, an endocrine disease. “The commitment from both new and existing investors provide us with the resources to advance our regulatory efforts, prepare for a successful launch of octreotide capsules, test oral octreotide capsules for additional indications and further invest in earlier-stage TPE programs that can fuel our growth over the long term,” said Roni Mamluk, Ph.D., chief executive officer of Chiasma in a press release. “With this financing in place, we are well positioned to advance a portfolio of oral drugs that address unmet needs in orphan indications.”